Free tool
FAERS Monitor: Visine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020485 or its brand name (Visine, Naphazoline Hydrochloride, Pheniramine Maleate). Reports on generic versions are filed under their own applications.
Reports
25
Serious
2
8% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye irritation10
- mydriasis7
- product use in unapproved indication7
- eye pain6
- expired product administered3
- vision blurred3
- eye swelling2
- adverse event1
- drug ineffective1
- eye allergy1
- eye pruritus1
- incorrect dose administered1
- lacrimation increased1
- ocular discomfort1
- ocular hyperaemia1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2024 | 11 |
| 2025 | 9 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,134 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eye allergy | 1 | 543.7 | 79.6 | 135 |
| mydriasisSignal | 7 | 459.2 | 244.9 | 2,759 |
| eye irritationSignal | 10 | 146.2 | 90.4 | 1,304 |
| eye painSignal | 6 | 89.5 | 44.5 | 441 |
| expired product administeredSignal | 3 | 75.9 | 26.3 | 153 |
| ocular discomfort | 1 | 74.9 | 11.0 | 18 |
| eye swelling | 2 | 45.2 | 12.0 | 48 |
| lacrimation increased | 1 | 27.8 | 4.1 | 6 |
| eye pruritus | 1 | 25.0 | 3.7 | 5 |
| product use in unapproved indicationSignal | 7 | 23.8 | 12.7 | 132 |
| vision blurredSignal | 3 | 18.4 | 6.4 | 34 |
| ocular hyperaemia | 1 | 17.7 | 2.6 | 3 |
| adverse event | 1 | 9.1 | 1.3 | 1 |
| incorrect dose administered | 1 | 3.7 | 0.5 | 0 |
| drug ineffective | 1 | 0.6 | 0.1 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.